Foresite Capital Management II’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-45,884
| Closed | -$7.9M | – | 4 |
|
|
2021
Q3 | $7.9M | Hold |
45,884
| – | – | 2.81% | 3 |
|
|
2021
Q2 | $5.76M | Hold |
45,884
| – | – | 1.55% | 4 |
|
|
2021
Q1 | $6.22M | Hold |
45,884
| – | – | 1.43% | 4 |
|
|
2020
Q4 | $5.87M | Hold |
45,884
| – | – | 1.55% | 4 |
|
|
2020
Q3 | $5.16M | Buy |
45,884
+11,100
| +32% | +$1.11M | 1.12% | 4 |
|
|
2020
Q2 | $3.31M | Hold |
34,784
| – | – | 0.65% | 3 |
|
|
2020
Q1 | $3.13M | Sell |
34,784
-153,818
| -82% | -$12M | 0.73% | 5 |
|
|
2019
Q4 | $10M | Hold |
188,602
| – | – | 1.65% | 5 |
|
|
2019
Q3 | $7.45M | Hold |
188,602
| – | – | 1.58% | 6 |
|
|
2019
Q2 | $7.75M | Hold |
188,602
| – | – | 4.36% | 6 |
|
|
2019
Q1 | $8.78M | Sell |
188,602
-21,000
| -10% | -$922K | 3.97% | 6 |
|
|
2018
Q4 | $9.13M | Sell |
209,602
-10,666
| -5% | -$533K | 4.84% | 6 |
|
|
2018
Q3 | $12.6M | Sell |
220,268
-24,488
| -10% | -$1.2M | 4.67% | 6 |
|
|
2018
Q2 | $11.9M | Hold |
244,756
| – | – | 4.18% | 6 |
|
|
2018
Q1 | $9.57M | Hold |
244,756
| – | – | 3.18% | 7 |
|
|
2017
Q4 | $10.4M | Hold |
244,756
| – | – | 3.63% | 6 |
|
|
2017
Q3 | $9.13M | Buy |
+244,756
| New | +$8.5M | 3.7% | 6 |
|
|
2017
Q2 | – | Sell |
-19,910
| Closed | -$527K | – | 15 |
|
|
2017
Q1 | $527K | Hold |
19,910
| – | – | 0.23% | 12 |
|
|
2016
Q4 | $508K | Buy |
+19,910
| New | +$631K | 0.25% | 9 |
|
|
2016
Q3 | – | Sell |
-48,839
| Closed | -$1.66M | – | 14 |
|
|
2016
Q2 | $1.66M | Sell |
48,839
-125,250
| -72% | -$4.07M | 1.13% | 12 |
|
|
2016
Q1 | $4.59M | Buy |
174,089
+36,631
| +27% | +$1.07M | 2.25% | 11 |
|
|
2015
Q4 | $6.7M | Sell |
137,458
-61,259
| -31% | -$2.2M | 2.25% | 13 |
|
|
2015
Q3 | $4.95M | Buy |
198,717
+167,617
| +539% | +$5.04M | 1.5% | 13 |
|
|
2015
Q2 | $984K | Buy |
+31,100
| New | +$1M | 0.35% | 20 |
|
Foresite Capital Management II's XLRN Position: Q4 2021 in Review
Foresite Capital Management II sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 45,884 shares — an estimated $7.9M sold.
Foresite Capital Management II first reported a position in XLRN in Q2 2015 and held it in 24 quarters. The position peaked at $12.6M in Q3 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Foresite Capital Management II reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Foresite Capital Management II sold 45,884 Acceleron Pharma shares in Q4 2021, an estimated $7.9M.
- Foresite Capital Management II first reported a position in Acceleron Pharma in Q2 2015 and held it in 24 quarters.
- Foresite Capital Management II's Acceleron Pharma position peaked at $12.6M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Foresite Capital Management II's 13F filing for Q4 2021, filed 11 Feb 2022.